Nature Communications (Oct 2022)
Stratifin as a novel diagnostic biomarker in serum for diffuse alveolar damage
- Noriaki Arakawa,
- Atsuhito Ushiki,
- Mitsuhiro Abe,
- Shinichiro Matsuyama,
- Yoshinobu Saito,
- Takeru Kashiwada,
- Yasushi Horimasu,
- Akihiko Gemma,
- Koichiro Tatsumi,
- Noboru Hattori,
- Kenji Tsushima,
- Keiko Miyashita,
- Kosuke Saito,
- Ryosuke Nakamura,
- Takeshi Toyoda,
- Kumiko Ogawa,
- Motonobu Sato,
- Kazuhiko Takamatsu,
- Kazuhiko Mori,
- Takayoshi Nishiya,
- Takashi Izumi,
- Yasuo Ohno,
- Yoshiro Saito,
- Masayuki Hanaoka
Affiliations
- Noriaki Arakawa
- Division of Medicinal Safety Science, National Institute of Health Sciences
- Atsuhito Ushiki
- First Department of Internal Medicine, Shinshu University School of Medicine
- Mitsuhiro Abe
- Department of Respirology, Graduate School of Medicine, Chiba University
- Shinichiro Matsuyama
- Division of Medicinal Safety Science, National Institute of Health Sciences
- Yoshinobu Saito
- Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School
- Takeru Kashiwada
- Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School
- Yasushi Horimasu
- Department of Respiratory Medicine, Hiroshima University Hospital
- Akihiko Gemma
- Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School
- Koichiro Tatsumi
- Department of Respirology, Graduate School of Medicine, Chiba University
- Noboru Hattori
- Department of Molecular and Internal Medicine, Graduate School of Biomedical & Health Sciences, Hiroshima University
- Kenji Tsushima
- Department of Pulmonary Medicine, School of Medicine, International University of Health and Welfare
- Keiko Miyashita
- Division of Medicinal Safety Science, National Institute of Health Sciences
- Kosuke Saito
- Division of Medicinal Safety Science, National Institute of Health Sciences
- Ryosuke Nakamura
- Division of Medicinal Safety Science, National Institute of Health Sciences
- Takeshi Toyoda
- Division of Pathology, National Institute of Health Sciences
- Kumiko Ogawa
- Division of Pathology, National Institute of Health Sciences
- Motonobu Sato
- Astellas Pharma Inc
- Kazuhiko Takamatsu
- Astellas Pharma Inc
- Kazuhiko Mori
- Daiichi Sankyo RD Novare Co., Ltd
- Takayoshi Nishiya
- Daiichi Sankyo RD Novare Co., Ltd
- Takashi Izumi
- Kihara Memorial Foundation
- Yasuo Ohno
- Kihara Memorial Foundation
- Yoshiro Saito
- Division of Medicinal Safety Science, National Institute of Health Sciences
- Masayuki Hanaoka
- First Department of Internal Medicine, Shinshu University School of Medicine
- DOI
- https://doi.org/10.1038/s41467-022-33160-9
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 16
Abstract
No reliable serum biomarker for diffuse alveolar damage, a poor prognosis subtype of drug-induced interstitial lung disease, is currently available. Here, the authors show stratifin/14-3-3σ in serum is a promising biomarker for diagnosis of this type of disease.
